Literature DB >> 7459239

Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability.

R E Leake, L Laing, K C Calman, F R Macbeth, D Crawford, D C Smith.   

Abstract

The concentration of cellular oestrogen receptor (RE) was measured in both the soluble and nuclear-pellet fractions of biopsies from 1,000 breast cancers. Data suggest that functional steroid RE is always in equilibrium between the soluble and nuclear fractions. However, biopsies from only one-third of patients contained detectable amounts of high-affinity RE in both fractions. Thirty patients out of 42 (71%) whose biopsies contained RE in both fractions, showed objective remission after receiving some form of hormonal manipulation as sole treatment. Response rates in the other categories ranged from 9% for those whose biopsies contained no detectable RE to 24% for those who displayed soluble RE alone. The presence of RE in both fractions of primary disease, whereas RE-negativity was maintained during progression from primary to secondary disease. Other aspects of RE status in relation to stage of disease are analysed.

Entities:  

Keywords:  Age Factors; Biology; Breast Cancer; Cancer; Clinic Activities; Diseases; Endocrine System; Estrogens; Histology; Hormone Receptors; Hormones; Membrane Proteins; Menopause; Neoplasms; Physiology; Reproduction

Mesh:

Substances:

Year:  1981        PMID: 7459239      PMCID: PMC2010491          DOI: 10.1038/bjc.1981.8

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

Review 1.  Clinical relevance of steroid-receptor measurements in tumours.

Authors:  R J King
Journal:  Cancer Treat Rev       Date:  1975-12       Impact factor: 12.111

2.  Distribution of the oestrogen-induced protein and of total protein between endometrial and myometrial fractions of the immature and mature rat uterus.

Authors:  B S Katzenellenbogen; R E Leake
Journal:  J Endocrinol       Date:  1974-12       Impact factor: 4.286

3.  A new assessment of subcellular distribution of bound estrogen in the uterus.

Authors:  D Williams; J Gorski
Journal:  Biochem Biophys Res Commun       Date:  1971-10-01       Impact factor: 3.575

4.  "False-positive" oestrogen-receptor assay in breast cancer.

Authors:  B A Stoll
Journal:  Lancet       Date:  1977-08-06       Impact factor: 79.321

5.  Estrogen receptors in hormone-dependent breast cancers.

Authors:  E V Jensen
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

6.  Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication.

Authors:  J S Meyer; B R Rao; S C Stevens; W L White
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

Review 7.  Current status of estrogen and progesterone receptors in breast cancer.

Authors:  W L McGuire; K B Horwitz; O H Pearson; A Segaloff
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

8.  Uncharged nuclear receptors for estrogen in breast cancers.

Authors:  W B Panko; R M MacLeod
Journal:  Cancer Res       Date:  1978-07       Impact factor: 12.701

9.  Inhibition of prostaglandin synthetase by anti-tumour agents.

Authors:  M J Tisdale
Journal:  Chem Biol Interact       Date:  1977-07       Impact factor: 5.192

10.  Nuclear oestrogen receptors and treatment of breast cancer.

Authors:  L Laing; M G Smith; K C Calman; D C Smith; R E Leake
Journal:  Lancet       Date:  1977-07-23       Impact factor: 79.321

View more
  23 in total

1.  Investigation of the origin of variant, truncated estrogen receptor-like mRNAs identified in some human breast cancer biopsy samples.

Authors:  L C Murphy; H Dotzlaw; J Hamerton; J Schwarz
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

2.  Nuclear binding of the estrogen receptor: a potential predictor for hormone response in metastatic breast cancer.

Authors:  N J Robert; L Martin; C D Taylor; J Popkin; D R Parkinson; C White; C A Pappas; H Tamura; R Gelman; J Cohen
Journal:  Breast Cancer Res Treat       Date:  1990-10       Impact factor: 4.872

3.  The effect of molybdate on the intracellular distribution of estrogen receptor in mammary tumors.

Authors:  C B Lazier; J Richman; K Lonergan
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

4.  Soluble and nuclear type I and II androgen-binding sites in benign hyperplasia and cancer of the human prostate.

Authors:  L Castagnetta; G Carruba; E Fecarotta; M Lo Casto; R Cusimano; M Pavone-Macaluso
Journal:  Urol Res       Date:  1992

5.  Estrogen receptor status as a prognostic indicator for stage I breast cancer patients.

Authors:  J P Crowe; C A Hubay; O H Pearson; J S Marshall; J Rosenblatt; E G Mansour; R E Hermann; J C Jones; W J Flynn; W L McGuire
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

6.  Steroid hormone receptors in human salivary gland tumours.

Authors:  P J Lamey; R E Leake; S K Cowan; D S Soutar; I A McGregor; F M McGregor
Journal:  J Clin Pathol       Date:  1987-05       Impact factor: 3.411

7.  Oestrogen receptor concentration in primary breast cancer and axillary node metastases.

Authors:  R A Hawkins; R Black; R J Steele; J M Dixon; A P Forrest
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

Review 8.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

9.  Do multiple oestrogen receptor assays give significant additional information for the management of breast cancer?

Authors:  L Castagnetta; A Traina; A Di Carlo; G Carruba; M Lo Casto; M Mesiti; R Leake
Journal:  Br J Cancer       Date:  1989-04       Impact factor: 7.640

10.  Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup.

Authors:  S Nicholson; J Richard; C Sainsbury; P Halcrow; P Kelly; B Angus; C Wright; J Henry; J R Farndon; A L Harris
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.